On the September 18th to 19th, the Smart China Expo’s important series of events, “2021 Conference on High Quality Development of Healthcare Industry and the 6th China Pharmaceutical R&D Innovation Summit” kicked off at Chongqing, China.
Shanghai Medicilon Inc. (Medicilon) was invited to participate in this event and was awarded the “Top Chinese R&D CRO Enterprises in 2021”.
“The only advantage of sustainable competition comes from the ability to innovate over competitors.” This sentence precisely explains why Medicilon is able to stand in the leading position. Always paying attention to the needs of the global pharmaceutical industry’s innovation and development and based on the key link of innovative drug R&D, Medicilon now has a research and development laboratory of 73,800 square meters, with a small molecule drug R&D platform with protein degradation technology (PROTAC) and kinase inhibitors, tumor immune drug efficacy evaluation, inhalation and ophthalmic drug evaluation, and AI-assisted new drug design and other innovative service platforms. It is because of not stingy to innovate and daring to make breakthroughs, Medicilon will be honored to be ranked No. 4 on the list.
The Top Chinese R&D CRO Enterprises in 2021 is comprehensively selected from multiple factors such as sales, profits and R&D investment. Medicilon was awarded “Top Chinese R&D CRO Enterprises in 2021”, which means this fully demonstrates the strong potential of Medicilon in the field of preclinical new drug R&D. This is affirmation and glory for Medicilon, and it is also the driving force for Medicilon to move forward.
As a professional biopharmaceutical preclinical R&D CRO, Medicilon will continue to cultivate in the field of pharmaceutical, to invest heavily and strive to become a leading innovative CRO in the industry, to create value for the pharmaceutical community, and to contribute the R&D of pharmaceutical in China.